Megan Wilder, | |
22115 Ne Chelatchie Rd, Amboy, WA 98601-3813 | |
(360) 885-6050 | |
Not Available |
Full Name | Megan Wilder |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 22115 Ne Chelatchie Rd, Amboy, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1629732508 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | LL61222784 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Megan Wilder, 10203 Nw 26th Ave, Vancouver, WA 98685-4812 Ph: () - | Megan Wilder, 22115 Ne Chelatchie Rd, Amboy, WA 98601-3813 Ph: (360) 885-6050 |
News Archive
"You are what you eat," the saying goes, but is what you eat playing a role in how much you sleep? Sleep, like nutrition and physical activity, is a critical determinant of health and well-being. With the increasing prevalence of obesity and its consequences, sleep researchers have begun to explore the factors that predispose individuals to weight gain and ultimately obesity.
Many of us are simply overloaded with cholesterol, and now a report in the July issue of Cell Metabolism brings what might be good news: There is more than one way to get rid of that cholesterol, which can otherwise lead to atherosclerosis and heart disease.
Accuray Incorporated, a global leader in the field of radiosurgery, announced today that the 100,000th patient has been treated with the CyberKnife® Robotic Radiosurgery System, a non-invasive alternative to surgery for the treatment of both cancerous and non-cancerous tumors anywhere in the body. One in four patients treated with CyberKnife radiosurgery received treatment during Accuray's fiscal 2010, which ran July 2009 to June 2010.
A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia, lymphoma and other blood disorders who have received a transplant of new, blood-forming cells.
› Verified 1 days ago